Does ENCORAFENIB Cause Neoplasm progression? 548 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 548 reports of Neoplasm progression have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 6.4% of all adverse event reports for ENCORAFENIB.
548
Reports of Neoplasm progression with ENCORAFENIB
6.4%
of all ENCORAFENIB reports
163
Deaths
107
Hospitalizations
How Dangerous Is Neoplasm progression From ENCORAFENIB?
Of the 548 reports, 163 (29.7%) resulted in death, 107 (19.5%) required hospitalization, and 6 (1.1%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 548 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
Serous retinal detachment (297)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which ENCORAFENIB Alternatives Have Lower Neoplasm progression Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN